Radiotherapy for breast cancer, the TARGIT - A trial (III)

The Lancet

Volumn 383, Issue 9930, 2014, Pages 1716-1717

  Haviland, Joanne S ^a   A'Hern, Roger ^b   Bentzen, Soeren M ^c   Whelan, Timothy ^d   Bliss, Judith M ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; INTRAOPERATIVE RADIOTHERAPY; LETTER; PRIORITY JOURNAL; RECURRENCE RISK; BREAST TUMOR; FEMALE; NOTE; PAGET NIPPLE DISEASE; CLINICAL TRIAL (TOPIC);

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS;

EID: 84900529306     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60826-6     Document Type: Letter

References (2)

1. Vaidya JS, Wenz F, Bulsara M., et al, on behalf of the TARGIT trialists' group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014; 383: 603-13.
2. Parmer MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 2008; 17: 2815-34.